VivoSim Labs

Name

VivoSim Labs

Legal name

VivoSim Labs, Inc.

Website

https://vivosim.ai

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Preclinical Toxicology Testing Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

Keywords

• 3D tissue models
• Preclinical toxicology testing
• Drug-induced liver injury
• Human-relevant safety assessment
• NAM-based drug screening

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Toxicology Testing Services: VivoSim Labs generates revenue through contracted toxicology testing services using NAMkind™ 3D liver and intestine models. Services include prospective screens (20+ compounds in 2 weeks), translational bridge studies, and investigative toxicology (1-2 compounds across multiple concentrations with 4-week turnaround). Standard liver service screens 36-40 compounds at 4 concentrations each with 17-day treatment period; GI service tests 30 compounds with 7-day exposure protocol.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.

Product overview

VivoSim Labs offers a unified portfolio of NAMkind™ 3D human tissue models and associated toxicology testing services. The core products include the NAMkind™ Liver Model (3D liver spheroids with hepatocytes, Kupffer cells, endothelial, and stellate cells) and the NAMkind™ Intestine Model (3D Transwell platform with epithelial and stromal cells). These models are offered alongside three service tiers: Liver Toxicology Services (standard screening of up to 40 compounds over 17 days), Gastrointestinal Toxicology Services (intestinal barrier assessment over 7 days with TEER and viability readouts), and Investigative Toxicology Services (mechanistic studies for at-risk compounds in 4 weeks). All offerings are aligned with FDA's New Approach Methodology (NAM) framework and leverage primary human cells to provide human-relevant safety data for drug development.

Differentiator

Problem solved

Functional benefit

Brands

• NAMkind: 3D human tissue models including liver and intestine models for toxicology testing and drug development.

Products and services

• Liver Toxicology Services Contracted toxicology testing service using the NAMkind™ Liver Model that screens up to 40 compounds at multiple concentrations over a 17-day treatment period, measuring viability, functional output, and DILI biomarkers (LDH release, albumin secretion, ATP viability, glutathione status). Includes optional mechanistic panels and species-specific variants (rat, mouse, dog, monkey). Designed for pharmaceutical and biotech teams during Hit-to-Lead, Lead Optimization, and Candidate Nomination.
• Gastrointestinal Toxicology Services Full-service intestinal toxicity testing using the NAMkind™ Intestine Model. Tests up to 30 compounds over a 7-day exposure protocol at four concentrations, assessing barrier function (TEER), cell viability (ATP, Alamar Blue), and histological changes with a 4-week turnaround. Targets pharmaceutical and biotech programs with high GI toxicity risk such as oncology and IBD.
• Investigative Toxicology Services On-demand mechanistic toxicology service using BioPrint 3D human tissue models to investigate unexpected compound-related toxicity signals. Supports 1-2 compounds across multiple concentrations with a 4-week turnaround, providing insights into cellular stress, tissue damage, and inflammatory signaling to support go/modify/stop decisions.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered regional.

• JCBioregionalChannel Partner/ Reseller/ DistributorKorean distribution partner for VivoSim products. Ensures hassle-free buying experience for customers in Korea. Listed on distributors page of VivoSim website alongside Tekon.
• TekonregionalChannel Partner/ Reseller/ DistributorChinese distribution partner (Tekon Biotech) for VivoSim products. Enables local access for customers in China. Listed alongside JCBio as regional distribution partners.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Emulate: Commercial-stage organ-on-chip company with Liver-Chip and Intestine-Chip products used by major pharma for preclinical safety assessment. Comparable to VivoSim's NAMkind portfolio in tissue types and target customers, though with a more capital-intensive chip platform.
• TissUse: Developer of multi-organ-chip microphysiological systems for toxicology and efficacy testing. Comparable to VivoSim as a NAM-focused tissue model company serving pharma R&D.

Broad incumbents

• Labcorp Drug Development (formerly Covance): Global CRO with a large preclinical toxicology practice, including emerging NAM offerings. Represents an incumbent competitor and potential partner for VivoSim's NAMkind services.
• Inotiv: Preclinical CRO offering toxicology, safety pharmacology, and research models. Comparable as an established alternative to VivoSim for outsourced preclinical toxicology studies.
• BioIVT: Supplier of primary human cells and in vitro test systems, including hepatocytes used in liver toxicology workflows. Comparable to VivoSim as a supplier into the human-relevant in vitro toxicology market, with potential partnership and overlap.
• Charles River Laboratories: Large preclinical CRO with extensive in vivo and in vitro toxicology service lines serving global pharma. Competes with VivoSim for preclinical safety spend and represents both a competitive threat and a potential partnership/buyer.

Direct peers

• MIMETAS: Offers OrganoPlate-based 3D tissue models and organ-on-chip toxicology screening services for pharmaceutical customers. Comparable to VivoSim on the technology axis (microfluidic 3D human tissue models) and the services business model.
• InSphero: Provider of 3D in vitro microtissue organoid models (liver, pancreas, etc.) for predictive toxicology and disease modeling. Closely comparable to VivoSim's NAMkind Liver platform in terms of primary-cell-based 3D spheroid technology and target customer base.
• Cyprotex (an Evotec company): Leading contract research organization specializing in in vitro and in silico ADME-Tox services, including liver and intestinal toxicity assays. Directly comparable to VivoSim as a commercial in vitro toxicology services provider for pharma and biotech.
• CN Bio: Developer of organ-on-chip and microphysiological systems, including liver and gut models for drug safety and efficacy testing. Direct peer to VivoSim in the NAM-based 3D tissue model space serving pharma preclinical safety applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/OfficialOrganovo
• LinkedInlinkedin.com/company/organovo-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VivoSim Labs